Our Story – Cytonics Corporation

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

Science Corner, Our StoryJanuary 20, 20261KViews 0Likes 0Comments

Most people talk about lifespan. We obsess over how long we live. What actually matters is healthspan. How long we stay strong, mobile, and pain-free. Living to 90 means very little if your joints fail you at 60. At Cytonics Corporation, our mission is simple: extend healthspan by protecting the biology that makes movement…

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

Science Corner, Investor Relations, Our StoryJanuary 6, 20261KViews 0Likes 0Comments

You may have seen the recent headlines regarding a breakthrough in "anti-aging injections" for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in joints). While the media is…

#62 🙏 Another Year Full of Gratitude

Joey Bose, Investor Relations, Our StoryDecember 26, 20251KViews 0Likes 0Comments

As the year concludes, Joey Bose reflects on gratitude towards investors, the Cytonics community, and the dedicated team. He emphasizes the importance of long-term commitment and support in their progress. Looking ahead to 2026, he encourages everyone to cherish time with loved ones and appreciate their contributions.

#57: 👎 Why Cytonics Turned Down VC

Investor Relations, Our StoryAugust 27, 20251KViews 0Likes 0Comments

Cytonics rejects venture capital, believing it stifles innovation and dilutes shareholder value. Instead, they rely on over $25 million raised from individual investors who prioritize genuine progress over quick exits. With a strong community of 7,000 shareholders, they emphasize equity crowdfunding as a pathway to democratized and collaborative biotech advancement.

#53 🧪 The Experiment That Started It All

Our Story, Science CornerJune 25, 20251KViews 0Likes 0Comments

The journey of developing a cartilage-protecting therapy began with a hypothesis about the A2M protein’s potential. Initial experiments showed A2M could significantly reduce cartilage destruction caused by osteoarthritis. This led to the creation of APIC™ and the more advanced CYT-108, which demonstrated remarkable efficacy in preclinical trials, paving the way for human clinical trials.

#51 🥋 When Injury Meets Innovation: Rener Gracie’s Journey to Cytonics

Investor Relations, Our StoryJune 1, 20251KViews 0Likes 0Comments

Rener Gracie, a renowned jiu-jitsu master, faced a career-threatening knee injury but found hope through APIC™ therapy during recovery. Impressed by its life-changing results, he became an investor and advocate for CYT-108, a groundbreaking biologic therapy for osteoarthritis, emphasizing grassroots medicine and challenging traditional pharmaceutical methods.

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

Investor Relations, Our Story, Joey BoseMay 27, 20251KViews 0Likes 0Comments

Cytonics has released a video featuring CEO Joey Bose, explaining how their therapy CYT-108 challenges Big Pharma by targeting osteoarthritis’s root causes, rather than just symptoms. The video discusses past successes with APIC, the science behind their approach, and future strategies. Viewers are encouraged to support the company as potential shareholders.

#49 🦈 When a Shark Asks the Right Questions

Our Story, Investor RelationsMay 14, 20252KViews 0Likes 0Comments

Cytonics CEO Joey Bose discussed their groundbreaking approach to osteoarthritis with investor Kevin O’Leary. The biotech firm has treated over 10,000 patients and developed a therapy, CYT-108, which has completed Phase 1 trials. With $15M raised from 6,000 everyday investors, Cytonics challenges traditional Big Pharma funding models.

#48 🎉Major Milestone: Last Patient Completes Phase 1 Clinical Trial

Investor Relations, Our StoryMarch 31, 20252KViews 0Likes 0Comments

Cytonics has completed its first-in-human trial for CYT-108, a recombinant protease inhibitor for knee osteoarthritis. The 22-patient Phase 1 study focused on safety and efficacy, providing data for an FDA IND application and Phase 2 protocol. This milestone boosts prospects for a disease-modifying therapy and enhances shareholder value.

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

Investor Relations, Our StoryMarch 25, 20251KViews 0Likes 0Comments

Cytonics is seeking $24 million to fund a Phase 2 Clinical Study for CYT-108, its innovative osteoarthritis therapy. This fundraising effort, in partnership with StartEngine, utilizes Regulation A+, allowing unaccredited investors to participate. CYT-108 offers unique protease inhibition benefits and builds on the success of its predecessor, the APIC system.

#46 📢 Critical Patent Issuance Protecting Lead Drug Candidate

Investor Relations, Our StoryMarch 8, 2025999Views 0Likes 0Comments

Cytonics Corporation has received US Patent No. US 12,195,521 B2 for its engineered A2M variant, CYT-108. This patent enhances its competitive position by expanding therapeutic applications and securing exclusivity for two decades. It strengthens barriers to entry, increases licensing opportunities, and supports funding initiatives for future product development.

#45 🚨 Major Phase 1 Study Milestone Achieved!

Science Corner, Investor Relations, Our StoryJanuary 17, 20252KViews 0Likes 0Comments

The first nine patients have completed the Phase 1 clinical trial of CYT-108, with no reported adverse events. This biologic therapy aims to treat osteoarthritis by targeting cartilage-degrading enzymes. The company plans to initiate Phase 2 trials and will launch an equity crowdfunding campaign to finance further development.

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

#62 🙏 Another Year Full of Gratitude

#57: 👎 Why Cytonics Turned Down VC

#53 🧪 The Experiment That Started It All

#51 🥋 When Injury Meets Innovation: Rener Gracie’s Journey to Cytonics

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

#49 🦈 When a Shark Asks the Right Questions

#48 🎉Major Milestone: Last Patient Completes Phase 1 Clinical Trial

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

#46 📢 Critical Patent Issuance Protecting Lead Drug Candidate

#45 🚨 Major Phase 1 Study Milestone Achieved!

Get fresh updates

Download Exclusive Investor Presentation & Stay Updated